Adjuvanted inactivated rabies virus-vectored Lassa virus vaccine in healthy adults: a phase 1 trial

1

Lassa fever, caused by the Lassa virus, leads to significant morbidity and mortality, particularly in West Africa.
2

The LASSARAB vaccine, developed from an attenuated rabies strain, aims to provide protection against Lassa virus.
3

A phase 1 trial enrolled 54 healthy adults to assess the safety and reactogenicity of the LASSARAB vaccine.
4

Participants were divided into four groups, receiving varying doses of LASSARAB or a control rabies vaccine.
5

The study monitored participants for safety and immunogenicity through day 61 post-vaccination.

Nature Medicine

by Justin R. Ortiz, Drishya Kurup, Adam C. Kaufman, Sabrine Ben Hamed, Allison M. LaRocco, Kirsten E. Lyke, Sarah M. Litts, Shrimati Datta, Yuanyuan Liang, Megan F. McGilvray, Jeannie A. Losignor, Jennifer J. Oshinsky, Kari V. Palmer, Ifayet PL Johnson-Mayo, Gabrielle Scher, Uthra Balakumar, Anisha Chandwani, Rekha R. Rapaka, Meagan E. Deming, Joel V. Chua, Christoph Wirblich, Wilbur H. Chen, Kathleen M. Neuzil, Marcela F. Pasetti, Matthias J. Schnell
June 9, 2026

1